Intra-Cellular Therapies, Inc.

Form 4

December 23, 2015

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box

if no longer subject to Section 16. Form 4 or Form 5

obligations

may continue.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

See Instruction 1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * LERNER RICHARD A

(First) (Middle) (Last)

C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST

29TH STREET

(Street)

(State)

NEW YORK, NY 10016

(City)

2. Issuer Name and Ticker or Trading

Symbol

Intra-Cellular Therapies, Inc. [ITCI]

3. Date of Earliest Transaction

(Month/Day/Year) 12/22/2015

4. If Amendment, Date Original

Filed(Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

Issuer

below)

X_ Director

Applicable Line)

Officer (give title

1. Title of 2. Transaction Date 2A. Deemed Security (Month/Day/Year) Execution Date, if (Instr. 3)

(Zip)

(Month/Day/Year)

3. 4. Securities TransactionAcquired (A) or Code (Instr. 8)

Disposed of (D) (Instr. 3, 4 and 5)

or

Securities Beneficially Owned Following Reported (A)

Transaction(s) (Instr. 3 and 4)

5. Amount of

Code V Amount (D) Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Conversion 3. Transaction Date 3A. Deemed (Month/Day/Year) Execution Date, if

5. Number of TransactionDerivative

6. Date Exercisable and **Expiration Date**

7. Title and Amour Underlying Securit

OMB APPROVAL

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

5. Relationship of Reporting Person(s) to

6. Individual or Joint/Group Filing(Check

6. Ownership

Form: Direct

X Form filed by One Reporting Person Form filed by More than One Reporting

(I)

(Instr. 4)

(Check all applicable)

10% Owner

Other (specify

7. Nature of

Ownership

(9-02)

(Instr. 4)

Indirect

(D) or Indirect Beneficial

Estimated average

burden hours per

Edgar Filing: Intra-Cellular Therapies, Inc. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		(Month/Day/Year)		(Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amo or Num of Sh
Stock Option (right to buy)	\$ 1.36	12/22/2015		G <u>(1)</u>		10,000	(2)	12/05/2016	Common Stock	10,0
Stock Option (right to buy)	\$ 1.36	12/22/2015		G <u>(1)</u>	10,000		<u>(2)</u>	12/05/2016	Common Stock	10,0
Stock Option (right to buy)	\$ 1.5	12/22/2015		G <u>(1)</u>		12,500	(2)	12/12/2017	Common Stock	12,5
Stock Option (right to buy)	\$ 1.5	12/22/2015		G <u>(1)</u>	12,500		(2)	12/12/2017	Common Stock	12,5
Stock Option (right to buy)	\$ 1.5	12/22/2015		G <u>(1)</u>		12,500	<u>(2)</u>	12/18/2018	Common Stock	12,5
Stock Option (right to buy)	\$ 1.5	12/22/2015		G <u>(1)</u>	12,500		<u>(2)</u>	12/18/2018	Common Stock	12,5
Stock Option (right to buy)	\$ 2.74	12/22/2015		G <u>(1)</u>		12,500	<u>(2)</u>	06/10/2020	Common Stock	12,5

Stock Option (right to buy)	\$ 2.74	12/22/2015	G <u>(1)</u>	12,500		(2)	06/10/2020	Common Stock	12,5
Stock Option (right to buy)	\$ 2.74	12/22/2015	G <u>(1)</u>		12,500	(2)	12/21/2020	Common Stock	12,5
Stock Option (right to buy)	\$ 2.74	12/22/2015	G <u>(1)</u>	12,500		(2)	12/21/2020	Common Stock	12,5
Stock Option (right to buy)	\$ 2.84	12/22/2015	G <u>(1)</u>		12,500	(2)	04/30/2022	Common Stock	12,5
Stock Option (right to buy)	\$ 2.84	12/22/2015	G <u>(1)</u>	12,500		(2)	04/30/2022	Common Stock	12,5
Stock Option (right to buy)	\$ 3.26	12/22/2015	G <u>(1)</u>		12,500	(2)	06/20/2023	Common Stock	12,5
Stock Option (right to buy)	\$ 3.26	12/22/2015	G(1)	12,500		<u>(2)</u>	06/20/2023	Common Stock	12,5
Stock Option (right to	\$ 3.26	12/22/2015	G <u>(1)</u>		20,000	(2)	06/20/2023	Common Stock	20,0

buy)

Stock Option (right to buy)	\$ 3.26	12/22/2015	G <u>(1)</u>	20,000		<u>(2)</u>	06/20/2023	Common Stock	20,0
Stock Option (right to buy)	\$ 16.86	12/22/2015	G <u>(1)</u>		20,000	06/30/2015	06/29/2024	Common Stock	20,0
Stock Option (right to buy)	\$ 16.86	12/22/2015	G <u>(1)</u>	20,000		06/30/2015	06/29/2024	Common Stock	20,0
Stock Option (right to buy)	\$ 26.58	12/22/2015	G <u>(1)</u>		20,000	06/16/2016	06/15/2025	Common Stock	20,0
Stock Option (right to buy)	\$ 26.58	12/22/2015	G <u>(1)</u>	20,000		06/16/2016	06/15/2025	Common Stock	20,0

Reporting Owners

Reporting Owner Name / Address	Relationships					
F	Director	10% Owner	Officer	Other		
LERNER RICHARD A						
C/O INTRA-CELLULAR THERAPIES, INC. 430 EAST 29TH STREET	X					
NEW YORK, NY 10016						

Reporting Owners 4

Signatures

/s/ Lawrence J. Hineline, Attorney-in-fact

12/23/2015

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The reporting person transferred this option as a gift to the Lerner Family Trust UAD 11/14/94 (the "Lerner Family Trust"). Dr. Lerner shares voting and investment control with respect to the shares held by the Lerner Family Trust.
- (2) All shares underlying this option have vested.
- (3) Dr. Lerner may be deemed to beneficially own securities held by the Lerner Family Trust UAD 11/14/94 (the "Lerner Family Trust"). Dr. Lerner disclaims beneficial ownership of securities held by the Lerner Family Trust except to the extent of his pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 5